Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lomustine is an oral chemotherapy drug classified as a nitrosourea alkylating agent. It is highly lipid-soluble and able to cross the blood-brain barrier, which makes it effective for treating brain cancers. Lomustine alkylates and cross-links DNA and RNA, preventing their replication and transcription, which leads to cell death. It is used as an anticancer agent, particularly for brain tumors and Hodgkin lymphoma, and is also used in veterinary oncology. Lomustine is not a protein, receptor, enzyme, or other typical molecular target, but rather acts as a chemical that damages nucleic acids in tumor cells[2][3][4][5][6].
Lomustine alkylates and cross-links DNA and RNA, preventing their replication and transcription, which leads to cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lomustine.